SOP Guide for Pharma

SOP for Endotoxin Testing in Aseptic Transdermal Patches

SOP for Endotoxin Testing in Aseptic Transdermal Patches

Standard Operating Procedure for Endotoxin Testing in Aseptic Transdermal Patches

1) Purpose

To establish a standardized procedure for conducting endotoxin testing in aseptic transdermal patches to ensure they are free from bacterial endotoxins that could cause pyrogenic reactions.

2) Scope

This SOP applies to the quality control (QC) and quality assurance (QA) departments responsible for endotoxin testing of aseptic transdermal patches.

3) Responsibilities

3.1 QC Analysts: Perform endotoxin tests according to the procedure.
3.2 QA Personnel: Review and approve test results and ensure compliance with the SOP.
3.3 Production Personnel: Provide samples and relevant documentation for testing.
3.4 Regulatory Affairs: Ensure that the endotoxin testing procedure complies with regulatory requirements.

4) Procedure

4.1 Preparation:

4.1.1 Collect samples of aseptic transdermal patches from the production batch as per the sampling plan.

4.1.2 Ensure all equipment and materials used for endotoxin testing are sterilized and ready for use.

4.2 Endotoxin Testing:
4.2.1 Sample Preparation:

4.2.1.1 Aseptically remove patches from their packaging.

4.2.1.2 Prepare the sample according to the Limulus Amebocyte Lysate (LAL) test protocol.

4.2.2 Test Execution:

4.2.2.1 Use aseptic techniques to add the sample to the LAL reagent.

4.2.2.2 Incubate the samples at 37°C ± 1°C for the time specified in the test method (usually 60 minutes).

4.2.2.3 Observe the samples for gel formation, which indicates the presence of endotoxins.

4.2.3 Post-Test Evaluation:

4.2.3.1 After the incubation period, check the test tubes for gel formation.

4.2.3.2 Record any positive results and calculate the endotoxin concentration based on the standard curve.

4.2.3.3 Document all observations and results accurately in the test records.

4.3 Acceptance Criteria:

4.3.1 Define acceptance criteria for endotoxins based on regulatory guidelines and product specifications.

4.3.2 Ensure that the transdermal patches meet the defined criteria before they are approved for release.

4.4 Documentation:

4.4.1 Record all test results, including test conditions, observations, and outcomes.

4.4.2 Maintain records of equipment calibration and maintenance.

4.5 Review and Approval:

4.5.1 QA personnel review test results for compliance with acceptance criteria.

4.5.2 Approve or reject batches based on test outcomes.

4.5.3 Ensure all documentation is complete and accurate before batch release.

5) Abbreviations, if any

SOP: Standard Operating Procedure
QC: Quality Control
QA: Quality Assurance
LAL: Limulus Amebocyte Lysate

6) Documents, if any

Endotoxin Test Records
Calibration Records
Test Method Protocols
Batch Manufacturing Records

7) Reference, if any

USP Chapter 85: Bacterial Endotoxins Test
ICH Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products

8) SOP Version

Version 1.0

Exit mobile version